Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics在评估用于肥胖的口服小分子GLP-1受体激动剂GSBR-1290的20亿ACCESS临床研究中给首批患者用药。
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics对第一批患者进行了接受腹口服小分子GLP-1受体激动剂GSBR-1290的20亿ACCESS临床研究。该研究评估该药在肥胖症中的作用。